Positive Phase 2b ICONA interim results for icosabutate in NASH patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeksOnce-daily oral icosabutate showed dose-dependent,...
BioGeneration Ventures BGV IV fund closes at €140 million
BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension,...
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, The Netherlands, 6 January 2021 – Intravacc, one of the leading translational research and...
Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
The four-year agreement provides benefits for portfolio companies of Forbion and BioGeneration Ventures (BGV) Lonza to provide de-risking, development and manufacturing services for large molecule biologics The agreement will streamline the gene to IND process,...
FIRST completes its investment in TargED for the development of Microlyse – a next-generation thrombolytic clot-busting drug
November 24th, 2020, Utrecht, the Netherlands TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht founded by Associate prof. Coen Maas, PhD, Steven de Maat, PhD, Marc van Moorsel and Kristof Vercruysse, raised EUR 1.35 million to...
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
• NST becomes a multi-asset clinical development company, beyond NASH• Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control• A third clinical development...
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
Munich, Germany, November 10, 2020 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round. The financing was led by Vesalius Biocapital III and joined by Novartis...
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
Ghent, Belgium – October 15, 2020 - Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has...
Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties
• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...
Synaffix wins Best Platform Technology at 7th Annual World ADC Awards
AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...